# Biotech Daily Digest ‚Äî 2025-12-09

**73 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 3 items
- Endpoints News: 17 items
- Fierce Biotech: 14 items
- MHRA ‚Äì News: 1 item
- arXiv q-bio: 38 items


## Eli Lilly Press Releases

- **[Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition](https://investor.lilly.com/news-releases/news-release-details/lilly-and-adverum-announce-expiration-and-completion-adverum)**  
  _Tue, 09 Dec 2025 08:28:00 -0500_  
  INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ¬†and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of

- **[Lilly declares first-quarter 2026 dividend](https://investor.lilly.com/news-releases/news-release-details/lilly-declares-first-quarter-2026-dividend)**  
  _Mon, 08 Dec 2025 14:05:00 -0500_  
  INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026 , to shareholders of record at the close of

- **[Carolyn Bertozzi returns to Lilly board of directors](https://investor.lilly.com/news-releases/news-release-details/carolyn-bertozzi-returns-lilly-board-directors)**  
  _Mon, 08 Dec 2025 10:00:00 -0500_  
  INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi , Ph.D., as a returning member, effective Dec. 8, 2025 . She will serve on the board's Science and Technology and Ethics and Compliance committees.


## Endpoints News

- **[#SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancer](https://endpoints.news/sabcs25-biontech-bms-unwrap-phase-2-data-for-pd-l1xvegf-bispecific-in-breast-cancer/)**  
  _Tue, 09 Dec 2025 12:31:42 +0000_  
  BioNTech and Bristol Myers Squibb on Tuesday shared positive mid-stage breast cancer results for their PD-L1xVEGF-A bispecific antibody, which they claim has the potential to be a treatment backbone across many different cancers.

 Combined with ...

- **[#ASH25: Eli Lilly's Jaypirca makes first-line case, but ceiling may be capped](https://endpoints.news/ash25-eli-lillys-jaypirca-makes-first-line-case-but-ceiling-may-be-capped/)**  
  _Tue, 09 Dec 2025 12:30:47 +0000_  
  ORLANDO, Fla. ‚Äî Fresh off an approval of Jaypirca last week in second-line leukemia patients, Eli Lilly is now looking to move up to the first-line setting with impressive data presented Tuesday.

 The results, revealed at ...

- **[#ASH25: Novartis says its antibody ianalumab helps prolong control of rare blood disorder](https://endpoints.news/ash25-novartis-says-its-antibody-ianalumab-helps-prolong-control-of-rare-blood-disorder/)**  
  _Tue, 09 Dec 2025 12:30:30 +0000_  
  Novartis said its latest experimental approach for a rare blood disorder prolonged patients‚Äô disease control by 45% compared to a placebo arm.

 The Phase 3 results, which follow a topline readout in ...

- **[Eli Lilly will be 'aggressive' in spending GLP-1 money, top dealmaker Van Naarden says](https://endpoints.news/eli-lilly-will-be-aggressive-in-spending-glp-1-money-says-top-dealmaker-van-naarden/)**  
  _Tue, 09 Dec 2025 12:30:22 +0000_  
  ORLANDO, Fla. ‚Äî Eli Lilly‚Äôs new chief dealmaker is planning to spend its GLP-1 cash in an ‚Äúaggressive‚Äù but responsible manner.

 Last month, Lilly‚Äôs president of oncology Jacob Van Naarden was

- **[Pfizer to pay $150M upfront for small molecule GLP-1 from Fosun subsidiary](https://endpoints.news/pfizer-to-pay-150m-upfront-for-small-molecule-glp-1-from-fosun-subsidiary/)**  
  _Tue, 09 Dec 2025 12:01:17 +0000_  
  On Nov. 19, Pfizer CFO Dave Denton said at the Jefferies Global Healthcare Conference that the large pharma was still looking for an oral small molecule for obesity and that it was ...

- **[Biosecure Act appears headed for final passage in defense bill](https://endpoints.news/biosecure-act-appears-headed-for-final-passage-in-defense-bill/)**  
  _Mon, 08 Dec 2025 20:17:06 +0000_  
  A softened version of the Biosecure Act has moved closer to final passage in Congress, but the bill could still shift US biopharma supply chains.

 On Sunday, House and Senate leadership released the text of ...

- **[FDA sets new, higher bar for CAR-T cancer treatments to prove superiority](https://endpoints.news/fda-sets-new-higher-bar-for-car-t-cancer-treatments-to-prove-superiority/)**  
  _Mon, 08 Dec 2025 19:57:56 +0000_  
  New CAR-T treatments for cancer will need to prove that they're better than existing therapies to win FDA approval, the agency's biologics chief Vinay Prasad said in a journal article Monday, raising the bar on ...

- **[#ASH25: Will a biotech‚Äôs pivot away from obesity let it compete with Novartis in leukemia?](https://endpoints.news/ash25-will-a-biotechs-pivot-away-from-obesity-let-it-compete-with-novartis-in-leukemia/)**  
  _Mon, 08 Dec 2025 19:45:58 +0000_  
  ORLANDO, Fla. ‚Äî In October, Terns Pharmaceuticals made an announcement that seemed to run counter to every popular sentiment in biotech: It got out of obesity to focus on cancer.

 The 9.4% stock drop that day ...

- **[GSK walks away from remaining Ideaya programs](https://endpoints.news/gsk-walks-away-from-remaining-ideaya-programs/)**  
  _Mon, 08 Dec 2025 18:55:55 +0000_  
  GSK is ending its licensing pact with Ideaya Biosciences after five years, handing two clinical programs back to the California-based biotech.

 Ideaya disclosed the news in an SEC filing Friday. It ...

- **[FDA misses PDUFA review deadline for Agios' thalassemia drug](https://endpoints.news/fda-misses-pdufa-review-deadline-for-agios-thalassemia-drug/)**  
  _Mon, 08 Dec 2025 18:08:34 +0000_  
  The FDA missed its target date for an approval decision on Agios‚Äô thalassemia drug, another delay for the company as it tries to expand its reach in blood disorders.

 A regulatory decision for Pyrukynd was ...

- **[Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approval](https://endpoints.news/dyne-says-duchenne-drug-succeeds-in-pivotal-study-heads-to-fda-for-approval/)**  
  _Mon, 08 Dec 2025 16:25:42 +0000_  
  Dyne Therapeutics announced Monday that its Duchenne muscular dystrophy drug hit the primary endpoint in a key study and plans to take the experimental treatment to the FDA for accelerated approval.

 Dyne is one of ...

- **[BioNTech, OncoC4‚Äôs antibody more than halves risk of death in Phase 3 lung cancer trial](https://endpoints.news/biontech-oncoc4s-antibody-more-than-halves-risk-of-death-in-phase-3-lung-cancer-trial/)**  
  _Mon, 08 Dec 2025 16:14:27 +0000_  
  BioNTech and OncoC4 shared positive survival data from a late-stage trial of their drug candidate in lung cancer that was previously hit with a partial hold by the FDA.

 The biotech‚Äôs treatment, called gotistobart, slashed ...

- **[Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant‚Äôs third SPAC](https://endpoints.news/day-one-was-one-of-three-parties-interested-in-mersana-bihua-chen-and-cormorants-third-spac/)**  
  _Mon, 08 Dec 2025 15:50:56 +0000_  
  Plus, news about Bicara Therapeutics, Boehringer Ingelheim, Gubra, AbbVie, OSE Immunotherapeutics, Encoded Therapeutics, UCB and Immix Biopharma:

 ü§ù Two other companies were interested in Mersana: Day One wasn‚Äôt the only company to submit offers ...

- **[#ASH25: Kura, Syndax detail data for rival menin inhibitors as both eye earlier use in AML](https://endpoints.news/ash25-kura-syndax-detail-data-for-rival-menin-inhibitors-as-both-eye-earlier-use-in-aml/)**  
  _Mon, 08 Dec 2025 15:45:18 +0000_  
  Kura Oncology and Kyowa Kirin said 73% of newly-diagnosed patients with certain forms of acute myeloid leukemia had a complete response after receiving their oral menin inhibitor.

 The early-stage results stoke their rivalry with Syndax ...

- **[Merck outbid three competitors in Cidara acquisition ‚Äî new filing](https://endpoints.news/merck-outbid-three-competitors-in-cidara-acquisition-new-filing/)**  
  _Mon, 08 Dec 2025 14:41:45 +0000_  
  Cidara Therapeutics commanded a highly competitive bidding war for its influenza antiviral, attracting acquisition proposals from four pharmaceutical companies, according to a Friday evening regulatory filing.

 Merck offered nearly 20% more ...

- **[Updated: Structure Therapeutics‚Äô obesity pill stacks up with Novo and Lilly; Ascletis also reports early results](https://endpoints.news/structure-therapeutics-obesity-pill-stacks-up-with-novo-and-lilly-ascletis-also-reports-early-results/)**  
  _Mon, 08 Dec 2025 14:04:26 +0000_  
  Structure Therapeutics' GLP-1 pill cut patients‚Äô body weight by a placebo-adjusted average of 11.3% at around eight and a half months.

 This is competitive with both Eli Lilly‚Äôs orforglipron and Novo Nordisk‚Äôs oral formulation of ...

- **[Updated: Wave Life Sciences‚Äô RNA obesity shot cuts fat and retains muscle, but appears to lag behind Lilly‚Äôs for now](https://endpoints.news/wave-life-sciences-says-its-rna-obesity-shot-cuts-fat-but-retains-muscle/)**  
  _Mon, 08 Dec 2025 12:30:29 +0000_  
  Wave Life Sciences‚Äô obesity therapy helped patients lose more fat mass and retain more muscle than low doses of Novo Nordisk‚Äôs Wegovy or Eli Lilly‚Äôs muscle-sparing candidate bimagrumab when compared across different clinical trials.  ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/pfizer-continues-renewed-obesity-push-2b-pact-fosun-units-glp-1-drug" hreflang="en">Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug</a>](https://www.fiercebiotech.com/biotech/pfizer-continues-renewed-obesity-push-2b-pact-fosun-units-glp-1-drug)**  
  _Dec 9, 2025 7:20am_  
  Pfizer‚Äôs recent bidding war for an obesity biotech clearly hasn‚Äôt satiated the pharma‚Äôs appetite for new GLP-1 therapies‚Äîat least going by this morning‚Äôs $1.9 billion biobucks deal.

- **[<a href="https://www.fiercebiotech.com/biotech/ash-novartis-details-ianalumabs-phase-3-win-rare-blood-disease" hreflang="en">ASH: Novartis details ianalumab's phase 3 win in rare blood disease</a>](https://www.fiercebiotech.com/biotech/ash-novartis-details-ianalumabs-phase-3-win-rare-blood-disease)**  
  _Dec 5, 2025 2:07pm_  
  Novartis is divulging details from ianalumab‚Äôs phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could delay the progression of patients to more serious forms of the disease

- **[<a href="https://www.fiercebiotech.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma" hreflang="en">ASH: J&amp;J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma</a>](https://www.fiercebiotech.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma)**  
  _Dec 8, 2025 9:50pm_  
  A proposed combination of Johnson & Johnson‚Äôs multiple myeloma bispecific Tecvayli has turned up positive trial data that could put some pressure on CAR T-cell therapies, including the company‚Äôs own Carvykti.

- **[<a href="https://www.fiercebiotech.com/biotech/gsk-cuts-cord-longtime-ideaya-collaboration-letting-go-2-programs" hreflang="en">GSK cuts the cord on Ideaya collaboration, letting go of 2 programs</a>](https://www.fiercebiotech.com/biotech/gsk-cuts-cord-longtime-ideaya-collaboration-letting-go-2-programs)**  
  _Dec 8, 2025 5:12pm_  
  GSK is walking away from Ideaya Biosciences after a five-year-long partnership that initially focused on three of Ideaya's synthetic lethality programs.

- **[<a href="https://www.fiercebiotech.com/biotech/fda-steers-cancer-car-t-developers-toward-randomized-superiority-trials-policy-shift" hreflang="en">FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift</a>](https://www.fiercebiotech.com/biotech/fda-steers-cancer-car-t-developers-toward-randomized-superiority-trials-policy-shift)**  
  _Dec 9, 2025 4:34am_  
  The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA‚Äôs biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to show superiority over existing treatments.

- **[<a href="https://www.fiercebiotech.com/biotech/novartis-pens-17b-dermatology-pact-ai-enabled-british-biotech" hreflang="en">Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech</a>](https://www.fiercebiotech.com/biotech/novartis-pens-17b-dermatology-pact-ai-enabled-british-biotech)**  
  _Dec 9, 2025 3:59am_  
  Novartis has tapped an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology conditions.

- **[<a href="https://www.fiercebiotech.com/biotech/ash-merck-mulls-future-polycythemia-program-while-takeda-takes-ph-3-victory-lap" hreflang="en">ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap</a>](https://www.fiercebiotech.com/biotech/ash-merck-mulls-future-polycythemia-program-while-takeda-takes-ph-3-victory-lap)**  
  _Dec 8, 2025 3:55pm_  
  Patients with polycythemia vera, a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. But the tide may finally be turning in their favor, as Merck & Co. and Takeda both presented new data on their different approaches for the disease at the‚Ä¶

- **[<a href="https://www.fiercebiotech.com/biotech/weight-loss-windfall-lilly-looks-become-backbone-global-innovation" hreflang="en">With weight loss windfall, Lilly looks to become ‚Äòbackbone‚Äô of global innovation: exec</a>](https://www.fiercebiotech.com/biotech/weight-loss-windfall-lilly-looks-become-backbone-global-innovation)**  
  _Dec 8, 2025 9:59am_  
  With the best-selling medication in the world in tirzepitide and a record-setting $1 trillion valuation to go with it, Eli Lilly is hardly hurting for cash. But money is only as good as what you spend it on, and the Indianapolis drugmaker has big plans to put its capital to good use: by becoming ‚Äúa backbone of the ove‚Ä¶

- **[<a href="https://www.fiercebiotech.com/medtech/fda-clears-resmed-ai-personalizing-cpap-settings" hreflang="en">FDA clears Resmed AI for personalizing CPAP settings</a>](https://www.fiercebiotech.com/medtech/fda-clears-resmed-ai-personalizing-cpap-settings)**  
  _Dec 8, 2025 11:38am_  
  Resmed believes its artificial intelligence-powered approach to personalizing its connected CPAP machines can lead to more restful nights for people with obstructive sleep apnea.

- **[<a href="https://www.fiercebiotech.com/biotech/dr-reddys-pens-370m-pact-rights-immuteps-phase-3-stage-immunotherapy-certain-markets" hreflang="en">Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets </a>](https://www.fiercebiotech.com/biotech/dr-reddys-pens-370m-pact-rights-immuteps-phase-3-stage-immunotherapy-certain-markets)**  
  _Dec 8, 2025 10:01am_  
  Dr. Reddy‚Äôs Laboratories is paying $20 million upfront for the rights to Immutep‚Äôs phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key markets.

- **[<a href="https://www.fiercebiotech.com/biotech/wave-structure-move-assets-clinical-ladder-biotechs-obesity-development-blitz-rolls" hreflang="en">Wave, Structure stocks double on obesity data readouts</a>](https://www.fiercebiotech.com/biotech/wave-structure-move-assets-clinical-ladder-biotechs-obesity-development-blitz-rolls)**  
  _Dec 8, 2025 9:55am_  
  Amid an outpouring obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as both companies saw their respective shares soar in early trading.

- **[<a href="https://www.fiercebiotech.com/biotech/mirum-nets-bluejay-and-its-phase-3-stage-hepatitis-drug-620m" hreflang="en">Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M</a>](https://www.fiercebiotech.com/biotech/mirum-nets-bluejay-and-its-phase-3-stage-hepatitis-drug-620m)**  
  _Dec 8, 2025 9:02am_  
  Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug.

- **[<a href="https://www.fiercebiotech.com/medtech/stryker-promotes-stiles-president-coo-lead-its-ma-growth-strategy" hreflang="en">Stryker promotes new president, COO to help lead its M&amp;A strategy</a>](https://www.fiercebiotech.com/medtech/stryker-promotes-stiles-president-coo-lead-its-ma-growth-strategy)**  
  _Dec 8, 2025 8:46am_  
  Stryker, which has been focused on acquisitions while streamlining its business core, promoted 27-year veteran Spencer Stiles to president and chief operating officer.

- **[<a href="https://www.fiercebiotech.com/sponsored/agc-biologics-leader-warns-looming-microbial-manufacturing-crunch" hreflang="en">Is biopharma facing a microbial manufacturing crunch?</a>](https://www.fiercebiotech.com/sponsored/agc-biologics-leader-warns-looming-microbial-manufacturing-crunch)**  
  _Dec 4, 2025 10:05am_  
  AGC Biologics‚Äô Dieter Kramer shares insights, data and possible solutions as demand for late-phase microbial capacity accelerates


## MHRA ‚Äì News

- **[Strengthening collaboration between the MHRA and the Department of Health Northern Ireland](https://www.gov.uk/government/news/strengthening-collaboration-between-the-mhra-and-the-department-of-health-northern-ireland)**  
  _2025-12-09T00:00:00Z_  
  The MHRA and Northern Ireland partners are working together to support innovation, enhance patient safety and ensure people in Northern Ireland benefit from world-class regulation.


## arXiv q-bio

- **[Evaluation of the infectivity of porcine epidemic diarrhea virus on swine vehicles after cleaning and disinfection](https://arxiv.org/abs/2512.06037)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06037v1 Announce Type: new 
Abstract: Biosecurity measures enforced by the swine industry are in place not only to protect a single farm, but also the vast community of interconnected swine farms. Vehicles play a role in disease movement and given that most pigs move throughout the system multiple times dur‚Ä¶

- **[Algorithmic design of "smart canopy" maize architectures that maximize light use efficiency](https://arxiv.org/abs/2512.06064)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06064v1 Announce Type: new 
Abstract: We present a computational framework that integrates functional-structural plant modeling (FSPM) with an evolutionary algorithm to optimize three-dimensional maize canopy architecture for enhanced light interception under high-density planting. The optimization revealed‚Ä¶

- **[Beyond Lux thresholds: a systematic pipeline for classifying biologically relevant light contexts from wearable data](https://arxiv.org/abs/2512.06181)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06181v1 Announce Type: new 
Abstract: Background: Wearable spectrometers enable field quantification of biologically relevant light, yet reproducible pipelines for contextual classification remain under-specified.
  Objective: To establish and validate a subject-wise evaluated, reproducible pipeline and act‚Ä¶

- **[Assessing the Information Content of Individual Spikes in Population-Level Models of Neural Spiking Activity](https://arxiv.org/abs/2512.06280)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06280v1 Announce Type: new 
Abstract: In the last decade, there have been major advances in clusterless decoding algorithms for neural data analysis. These algorithms use the theory of marked point processes to describe the joint activity of many neurons simultaneously, without the need for spike sorting. I‚Ä¶

- **[Interpretable Neural Approximation of Stochastic Reaction Dynamics with Guaranteed Reliability](https://arxiv.org/abs/2512.06294)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06294v1 Announce Type: new 
Abstract: Stochastic Reaction Networks (SRNs) are a fundamental modeling framework for systems ranging from chemical kinetics and epidemiology to ecological and synthetic biological processes. A central computational challenge is the estimation of expected outputs across initial‚Ä¶

- **[Quantification of Planar Cortical Magnification with Optimal Transport and Topological Smoothing](https://arxiv.org/abs/2512.06492)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06492v1 Announce Type: new 
Abstract: The human visual system exhibits non-uniform spatial resolution across the visual field, which is characterized by the cortical magnification factor (CMF) that reflects its anatomical basis. However, current approaches for quantifying CMF using retinotopic maps derived‚Ä¶

- **[PRIMRose: Insights into the Per-Residue Energy Metrics of Proteins with Double InDel Mutations using Deep Learning](https://arxiv.org/abs/2512.06496)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06496v1 Announce Type: new 
Abstract: Understanding how protein mutations affect protein structure is essential for advancements in computational biology and bioinformatics. We introduce PRIMRose, a novel approach that predicts energy values for each residue given a mutated protein sequence. Unlike previous‚Ä¶

- **[Genetic Profile-Based Drug Sensitivity Prediction in Acute Myeloid Leukemia Patients Using SVR](https://arxiv.org/abs/2512.06709)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06709v1 Announce Type: new 
Abstract: Acute Myeloid Leukemia (AML) is a highly aggressive blood cancer with low survival rates. Hence, emphasizing the importance of the urgent need for effective treatment modalities. In recent times, the advances in cancer genomics have increased our understanding of AML, a‚Ä¶

- **[Visual Function Profiles via Multi-Path Aggregation Reveal Neuron-Level Responses in the Drosophila Brain](https://arxiv.org/abs/2512.06934)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06934v1 Announce Type: new 
Abstract: Accurately predicting individual neurons' responses and spatial functional properties in complex visual tasks remains a key challenge in understanding neural computation. Existing whole-brain connectome models of Drosophila often rely on parameter assumptions or deep le‚Ä¶

- **[Structure-conditioned input-to-state stability for layer-by-layer molecular computations in parallel chemical reaction networks](https://arxiv.org/abs/2512.07116)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.07116v1 Announce Type: new 
Abstract: Molecular computation in chemical reaction networks (CRNs) now constitutes a foundational framework for designing programmable biological systems. However, prevailing design methodologies primarily treat parallelism of chemical reactions as a liability, consequently mot‚Ä¶

- **[The emergence and diversification of dog morphology](https://arxiv.org/abs/2512.07413)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.07413v1 Announce Type: new 
Abstract: Dogs exhibit an exceptional range of morphological diversity as a result of their long-term association with humans. Attempts to identify when dog morphological variation began to expand have been constrained by the limited number of Pleistocene specimens, the fragmenta‚Ä¶

- **[Memory-Amortized Inference: A Topological Unification of Search, Closure, and Structure](https://arxiv.org/abs/2512.05990)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05990v1 Announce Type: cross 
Abstract: Contemporary ML separates the static structure of parameters from the dynamic flow of inference, yielding systems that lack the sample efficiency and thermodynamic frugality of biological cognition. In this theoretical work, we propose \textbf{Memory-Amortized Inferen‚Ä¶

- **[Investigating the effect of adaptive optimal control function in epidemic dynamics: predictions and strategy evolution based on SIR/V game theoretic framework](https://arxiv.org/abs/2512.06021)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06021v1 Announce Type: cross 
Abstract: In this paper, we consider an adaptive optimal control problem for an SIR/V epidemic model with human behavioral effects.We develop a model where effective management of infectious diseases are monitored by the means of non pharmaceutical interventions.This study deve‚Ä¶

- **[Spatial Analysis for AI-segmented Histopathology Images: Methods and Implementation](https://arxiv.org/abs/2512.06116)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06116v1 Announce Type: cross 
Abstract: Quantitatively characterizing the spatial organization of cells and their interaction is essential for understanding cancer progression and immune response. Recent advances in machine intelligence have enabled large-scale segmentation and classification of cell nuclei‚Ä¶

- **[Physics-Informed Neural Koopman Machine for Interpretable Longitudinal Personalized Alzheimer's Disease Forecasting](https://arxiv.org/abs/2512.06134)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06134v1 Announce Type: cross 
Abstract: Early forecasting of individual cognitive decline in Alzheimer's disease (AD) is central to disease evaluation and management. Despite advances, it is as of yet challenging for existing methodological frameworks to integrate multimodal data for longitudinal personaliz‚Ä¶

- **[Synergistic Computational Approaches for Accelerated Drug Discovery: Integrating Quantum Mechanics, Statistical Thermodynamics, and Quantum Computing](https://arxiv.org/abs/2512.06141)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06141v1 Announce Type: cross 
Abstract: Accurately predicting protein-ligand binding free energies (BFEs) remains a central challenge in drug discovery, particularly because the most reliable methods, such as free energy perturbation (FEP), are computationally intensive and difficult to scale. Here, we intr‚Ä¶

- **[Small Language Models Can Use Nuanced Reasoning For Health Science Research Classification: A Microbial-Oncogenesis Case Study](https://arxiv.org/abs/2512.06502)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06502v1 Announce Type: cross 
Abstract: Artificially intelligent (AI) co-scientists must be able to sift through research literature cost-efficiently while applying nuanced scientific reasoning. We evaluate Small Language Models (SLMs, <= 8B parameters) for classifying medical research papers. Using literat‚Ä¶

- **[On fine-tuning Boltz-2 for protein-protein affinity prediction](https://arxiv.org/abs/2512.06592)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06592v1 Announce Type: cross 
Abstract: Accurate prediction of protein-protein binding affinity is vital for understanding molecular interactions and designing therapeutics. We adapt Boltz-2, a state-of-the-art structure-based protein-ligand affinity predictor, for protein-protein affinity regression and ev‚Ä¶

- **[Leveraging Pre-trained Neural Network Models for the Classification of Tumor Cells Analyzed by Label-free Phase Holotomographic Microscopy](https://arxiv.org/abs/2512.06808)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06808v1 Announce Type: cross 
Abstract: Can a single label-free image reveal whether cancer cells were exposed to chemotherapy? We present an innovative methodology on the label-free and high-resolution imaging properties of phase holotomographic microscopy coupled with neural network models for the classif‚Ä¶

- **[Self-organized criticality in complex model ecosystems](https://arxiv.org/abs/2512.06961)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.06961v1 Announce Type: cross 
Abstract: We show that spatial extensions of many-species population dynamics models, such as the Lotka-Volterra model with random interactions we focus on in this work, generically exhibit scale-free correlation functions of population sizes in the limit of an infinite number‚Ä¶

- **[Self-Supervised Learning on Molecular Graphs: A Systematic Investigation of Masking Design](https://arxiv.org/abs/2512.07064)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.07064v1 Announce Type: cross 
Abstract: Self-supervised learning (SSL) plays a central role in molecular representation learning. Yet, many recent innovations in masking-based pretraining are introduced as heuristics and lack principled evaluation, obscuring which design choices are genuinely effective. Thi‚Ä¶

- **[Big shells, bigger data: cohort analysis of Chesapeake Bay Crassostrea virginica reefs](https://arxiv.org/abs/2512.07080)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.07080v1 Announce Type: cross 
Abstract: Oysters in Virginia Chesapeake Bay oyster reefs are "age-truncated", possibly due to a combination of historical overfishing, disease epizootics, environmental degradation, and climate change. Research has suggested that oysters exhibit resilience to environmental str‚Ä¶

- **[PlantBiMoE: A Bidirectional Foundation Model with SparseMoE for Plant Genomes](https://arxiv.org/abs/2512.07113)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.07113v1 Announce Type: cross 
Abstract: Understanding the underlying linguistic rules of plant genomes remains a fundamental challenge in computational biology. Recent advances including AgroNT and PDLLMs have made notable progress although, they suffer from excessive parameter size and limited ability to m‚Ä¶

- **[A Structured Review of Fixed and Multimodal Sensing Techniques for Bat Monitoring](https://arxiv.org/abs/2512.07153)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.07153v1 Announce Type: cross 
Abstract: Effective monitoring of mobile animal populations is crucial for ecological research, wildlife management, and agricultural applications. Monitoring of bats specifically can help understand the spread of disease as well as shine light on bat migration patterns, popula‚Ä¶

- **[Mapping Still Matters: Coarse-Graining with Machine Learning Potentials](https://arxiv.org/abs/2512.07692)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.07692v1 Announce Type: cross 
Abstract: Coarse-grained (CG) modeling enables molecular simulations to reach time and length scales inaccessible to fully atomistic methods. For classical CG models, the choice of mapping, that is, how atoms are grouped into CG sites, is a major determinant of accuracy and tra‚Ä¶

- **[Universal bounds on entropy production from fluctuating coarse-grained trajectories](https://arxiv.org/abs/2512.07772)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.07772v1 Announce Type: cross 
Abstract: Entropy production is arguably the most universally applicable measure of non-equilibrium behavior, particularly for systems coupled to a heat bath. This setting encompasses driven soft matter as well as biomolecular, biochemical, and biophysical systems. Despite its‚Ä¶

- **[Two waves of adaptation: speciation induced by dormancy in a model with changing environment](https://arxiv.org/abs/2410.10890)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2410.10890v2 Announce Type: replace 
Abstract: We consider a population model in which the season alternates between winter and summer, and individuals can acquire mutations either that are advantageous in the summer and disadvantageous in the winter, or vice versa. Also, we assume that individuals in the popula‚Ä¶

- **[A mathematical model for smooth muscle cell phenotype switching in atherosclerotic plaque](https://arxiv.org/abs/2412.06170)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2412.06170v2 Announce Type: replace 
Abstract: Smooth muscle cells (SMCs) play a fundamental role in the development of atherosclerotic plaques. They ingest lipids in a similar way to monocyte-derived macrophages (MDMs) in the plaque. This can stimulate SMCs to undergo a phenotypic switch to a macrophage-like ph‚Ä¶

- **[A Behaviour and Disease Model of Testing and Isolation](https://arxiv.org/abs/2504.02488)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2504.02488v2 Announce Type: replace 
Abstract: There has been interest in the interactions between infectious disease dynamics and behaviour for most of the history of mathematical epidemiology. This has included consideration of which mathematical models best capture each phenomenon, as well as their interactio‚Ä¶

- **[Resting State Functional Connectivity Patterns Associate with Alcohol Use Disorder Characteristics: Insights from the Triple Network Model](https://arxiv.org/abs/2504.06199)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2504.06199v2 Announce Type: replace 
Abstract: Prolonged alcohol use results in neuroadaptations that mark more severe and treatment-resistant alcohol use. The goal of this study was to identify functional connectivity brain patterns underlying Alcohol Use Disorder (AUD)-related characteristics in fifty-five adu‚Ä¶

- **[Theoretical limits for sensing through phase separation](https://arxiv.org/abs/2507.19021)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2507.19021v2 Announce Type: replace 
Abstract: Biomolecular condensates form on timescales of seconds in cells upon environmental or compositional changes. Condensate formation is thus argued to act as a mechanism for sensing such changes and quickly initiating downstream processes, such as forming stress granul‚Ä¶

- **[Beyond the Clinic: A Large-Scale Evaluation of Augmenting EHR with Wearable Data for Diverse Health Prediction](https://arxiv.org/abs/2509.22920)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2509.22920v2 Announce Type: replace 
Abstract: Electronic health records (EHRs) provide a powerful basis for predicting the onset of health outcomes. Yet EHRs primarily capture in-clinic events and miss aspects of daily behavior and lifestyle containing rich health information. Consumer wearables, by contrast, c‚Ä¶

- **[Anatomical basis of sex differences in the electrocardiogram identified by three-dimensional torso-heart imaging reconstruction pipeline](https://arxiv.org/abs/2312.13976)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2312.13976v4 Announce Type: replace-cross 
Abstract: The electrocardiogram (ECG) is used for diagnosis and risk stratification in myocardial infarction (MI). Women have a higher incidence of missed MI diagnosis and complications following infarction, and to address this we aim to provide quantitative information‚Ä¶

- **[PhyloLM : Inferring the Phylogeny of Large Language Models and Predicting their Performances in Benchmarks](https://arxiv.org/abs/2404.04671)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2404.04671v5 Announce Type: replace-cross 
Abstract: This paper introduces PhyloLM, a method adapting phylogenetic algorithms to Large Language Models (LLMs) to explore whether and how they relate to each other and to predict their performance characteristics. Our method calculates a phylogenetic distance metric‚Ä¶

- **[Artificial Human Intelligence: The role of Humans in the Development of Next Generation AI](https://arxiv.org/abs/2409.16001)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2409.16001v3 Announce Type: replace-cross 
Abstract: Human intelligence, the most evident and accessible form of source of reasoning, hosted by biological hardware, has evolved and been refined over thousands of years, positioning itself today to create new artificial forms and preparing to self--design their ev‚Ä¶

- **[Thermodynamic bounds on energy use in quasi-static Deep Neural Networks](https://arxiv.org/abs/2503.09980)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2503.09980v3 Announce Type: replace-cross 
Abstract: The rapid growth of deep neural networks (DNNs) has brought increasing attention to their energy use during training and inference. Here, we establish the thermodynamic bounds on energy consumption in quasi-static analog DNNs by mapping modern feedforward arch‚Ä¶

- **[Look the Other Way: Designing 'Positive' Molecules with Negative Data via Task Arithmetic](https://arxiv.org/abs/2507.17876)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2507.17876v2 Announce Type: replace-cross 
Abstract: The scarcity of molecules with desirable properties (i.e., `positive' molecules) is an inherent bottleneck for generative molecule design. To sidestep such obstacle, here we propose molecular task arithmetic: training a model on diverse and abundant negative e‚Ä¶

- **[Correlation-Weighted Communicability Curvature as a Structural Driver of Dengue Spread: A Bayesian Spatial Analysis of Recife (2015-2024)](https://arxiv.org/abs/2512.00315)**  
  _Tue, 09 Dec 2025 00:00:00 -0500_  
  arXiv:2512.00315v2 Announce Type: replace-cross 
Abstract: We investigate whether the structural connectivity of urban road networks helps explain dengue incidence in Recife, Brazil (2015--2024). For each neighborhood, we compute the average \emph{communicability curvature}, a graph-theoretic measure capturing the abi‚Ä¶
